# Select optimal tissue specimen for a successful Precise<sup>™</sup> Tumor or MyChoice<sup>®</sup> CDx test

### **Specimen selection**

		MyChoice CDx	PreciseTumor	PD-L1
Cancer type	Ovarian, fallopian tube, and primary peritoneal cancer	<b>✓</b>	<b>✓</b>	<b>✓</b>
	All other tumor types	Ø	<b>✓</b>	<b>✓</b>
Fixative	10% neutral buffered formalin	<b>✓</b>	<b>✓</b>	<b>✓</b>
	Formalin and alcohol mixture	<b>✓</b>	✓	✓
	Any other fixative	<b>✓</b>	Ø	Ø
Specimen	Frozen section tissue	<b>✓</b>	Ø	Ø
types	Cytology cell block	<b>✓</b>	<b>✓</b>	<b>✓</b>
	Most recent procedure recommended	Ø	<b>✓</b>	✓
Exclusions	Brain tissue	Ø	<b>✓</b>	<b>✓</b>
	Acid decalcification	Ø	Ø	Ø
	EDTA decalcification	<b>✓</b>	<b>✓</b>	<b>✓</b>
	Endometrium	Ø	<b>✓</b>	<b>✓</b>

1

### **Chemotherapy-naive**

Ideal specimen are chemotherapy-naive tumors from primary debulking surgery or biopsy. 2

### **Chemotherapy-treated\***

If patient has received neoadjuvant therapy, chemotherapy-treated tumors from primary debulking surgery may be submitted, but chemotherapy-naive tumor from biopsy is preferred.

\*Pre-treatment biopsy samples should be considered in patients with complete or near-complete treatment response

3

#### **Biopsy**

If debulking doesn't provide sufficient tumor, pretreatment biopsy samples should be considered. 4

#### Cytology

Cytology cell blocks (e.g., ascites fluid) are acceptable but tumor content must exceed 30%.
Unfixed cytology samples are not appropriate for genomic testing.



### Single test order

Blocks\*

At least one tumor block with a cross-sectional tumor area of  $25 mm^2 \, containing$  at least 40  $\mu m$  of tumor should be chosen for testing

**Slides** 

# If only tumor slides are available, preparation instructions below

- Cut and label one 5μm section for H&E staining on a charged slide
- Cut and label 5 µm sections on uncharged slides:

Area of tumor (mm²) with ≥30% tumor	# of 5µm unstained slides
20-25	8
15-19	12
10-14	16
5-9	20

- If cutting 10 μm sections, please label on slide "10μm"

## Multiple test order

At least one tumor block with a cross-sectional tumor area of 25mm<sup>2</sup> containing at least 80µm of tumor should be chosen for testing

If only tumor slides are available, preparation instructions below should be followed:

- Cut and label two 5µm sections for H&E staining on a charged slide.
- Cut and label 5µm sections on uncharged slides:

Area of tumor (mm²) with ≥ 30% tumor	# of 5µm unstained slides
20-25	16
15-19	24
10-14	32
5-9	40

- If cutting 10μm sections, please label on slide "10μm"

### PD-L1 Specimen

Can be performed on the tumor specimen FFPE block if provided, or:

- Additional 1-2 sections of 4-5 microns thickness provided on unstained, unbaked, positively charged slides
- A minimum of 50-100 tumor nuclei present

For small biopsies, try to submit at least 15 to 20 sections from 6 to 8 cores

For small biopsies, try to submit at least 15 to 20 sections from 6 to 8 cores

# **Preparation and fixation of samples**

	10% neutral buffered formalin (NBF) is preferred, but others will be accepted.				
Fixative	Fixation time should not exceed 72 hours.				
	Fixative should be freshly diluted from stock within the previous 24 hours.				
	Fixation should take a suggested minimum of 6 hours and a maximum of 72 hours. This will help reduce fixative artifacts from over fixation which can adversely affect the success of genetic testing.				
	Fixative penetrates tissue at a rate of -1mm/hr. Large specimens should be opened or incised to promote formalin penetration and reduce autolysis, which can adversely affect the success of testing.				
	Cytology samples must be spun, embedded into cell blocks and fixed in formalin. They can then be assessed for neoplastic cell content the same way as tissue samples.				
Collection	Specimen Handling	Specimens should be handled using a 'genome-friendly' protocol that minimizes nucleic acid damage, but maximizes nucleic acid recovery while also preserving tissue morphology.			
	Resection Specimen	Resection specimens should be delivered to pathology and undergo sample selection ideally within 1 hour of surgical excision.			
	Biopsy specimen	Recommended to obtain additional core with a dedicated block for Myriad testing.			
	Biopsy to fixative time	Tissue should go directly into fixative or degradation can occur.			
	Ratio of fixative to tissue	30% ideal, 20% minimum			
	Type of tissue	Ensure normal tissue is sampled before abnormal tissue to minimize contamination.  Previously frozen tissue is accepted.			
	Fixation before processing time	At least 8 hours but less than 36 hours is optimal for DNA*  *Fixation times longer than 72 hours should only be used when characteristics of the specimen demand it.			
	Chemical 1 on processor	10% NBF preferred.  Time here counts against time in fixative (less than 36 hours total).			
n B	Chemical 2 on processor	Alcohol is standard in increasing strengths to dehydrate tissue.			
Processing	Chemical 3 on processor (Clearing agent)	Xylene is preferred. (Let Myriad AP lab know if substitute is used.)			
	Processor run time	Typically runs overnight.  Less than 4 hours not optimal.			
MyChoice® CDx prep	Slides or blocks	DNA is more stable in blocks than slides, so blocks preferred.			
	Slide prep	Uncharged slides preferred makes it easier for macro dissection.			
	Refrigeration	Ice block must be sent to prevent the wax in the blocks/slides from melting.  Heat can also damage DNA.			
	Labeling	Sample containers must be clearly labeled according to institutional standards with an acceptable set of unique identifiers corresponding to information on the accompanying test request form.			

If you have any questions about your specimen submission or to obtain additional kits, please call our dedicated Precise Oncology Solutions Customer Service at 877-283-6709 or email helpmed@myriad.com.

Myriad, Precise Tumor, MyChoice CDx, and their logos are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the United States and Other jurisdictions. ©2022, Myriad Genetic Laboratories, Inc. in the

